These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6300502)

  • 1. Epstein-Barr virus-related lymphocyte stimulation inhibitor: a possible prognostic tool for undifferentiated nasopharyngeal carcinoma.
    Kamaraju LS; Levine PH; Sundar SK; Ablashi DV; Faggioni A; Armstrong GR; Bertram G; Krueger GR
    J Natl Cancer Inst; 1983 Apr; 70(4):643-7. PubMed ID: 6300502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical usefulness of the serological study of IgG antibodies and IgA against the antigens associated with the Epstein-Barr virus in patients with nasopharyngeal carcinoma].
    Amador García JM; Mendoza Montero J; Expósito Hernández J; Salinero Hernández J; Esquivias López-Cuerpo J; Ballesteros García P
    Acta Otorrinolaringol Esp; 1992; 43(1):31-6. PubMed ID: 1316136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP; Hsu CL; Chang YL; Tsang NM; Chen CK; Lee TJ; Tsao KC; Huang CG; Chang YS; Yu JS; Hao SP
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunoglobulin A serum antibodies against the capsid antigen of Epstein-Barr virus in the differential diagnosis and follow-up of nasopharyngeal cancer].
    Pavelka R; Popow-Kraupp T; Radaszkiewicz T
    Wien Klin Wochenschr; 1985 Jul; 97(14):588-95. PubMed ID: 2996246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum anti-EBV IgA is inversely related to tumor infiltration by surface IgA positive lymphocytes in nasopharyngeal carcinoma.
    Gunvén P; Klein G; Henle W; Henle G; Forsby N
    Biomed Pharmacother; 1983; 37(1):41-4. PubMed ID: 6311307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasopharyngeal carcinoma and Epstein-Barr virus--associated serologic markers.
    Tam JS; Murray HG
    Ear Nose Throat J; 1990 Apr; 69(4):261-7. PubMed ID: 2161732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The diagnosis of nasopharyngeal carcinoma (author's transl)].
    Arnold W; Nakazima A; Wang YB; Vosteen KH; Brunner H; Göbel U
    HNO; 1980 Aug; 28(8):247-60. PubMed ID: 6254933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus antibodies in Sudanese patients with nasopharyngeal carcinoma: a preliminary report.
    Malik MO; Banatvala J; Hutt MS; Abu-Sin AY; Hidaytallah A; El-Hadi AE
    J Natl Cancer Inst; 1979 Feb; 62(2):221-4. PubMed ID: 216831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Elevated Epstein-Barr virus antibodies in patients with Hodgkin's disease].
    Kuljić-Kapulica N
    Srp Arh Celok Lek; 1998; 126(3-4):97-100. PubMed ID: 9863363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sera from patients with undifferentiated nasopharyngeal carcinoma contain a factor which abrogates specific Epstein-Barr virus antigen-induced lymphocyte response.
    Sundar SK; Ablashi DV; Kamaraju LS; Levine PH; Faggioni A; Armstrong GR; Pearson GR; Krueger GR; Hewetson JF; Bertram G; Sesterhenn K; Menezes J
    Int J Cancer; 1982 Apr; 29(4):407-12. PubMed ID: 6282765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic markers for Epstein-Barr virus in the control of nasopharyngeal carcinoma and Burkitt lymphoma.
    Levine PH
    Cancer Detect Prev Suppl; 1987; 1():217-23. PubMed ID: 2826001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
    J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of the Epstein-Barr herpesvirus relationship with Hodgkin's disease and the use of virus immunological markers in differential diagnostics of nasopharyngeal carcinoma.
    Mazurenko NP; Gurtsevich VE; Stepina VN; Plakhov IV
    Arch Geschwulstforsch; 1983; 53(3):253-9. PubMed ID: 6311138
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.